- Home
- CWBC vs RIGL Comparison
CWBC vs RIGL Comparison
Compare CWBC & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWBC
- RIGL
- Stock Information
- Founded
- CWBC 1989
- RIGL 1996
- Country
- CWBC United States
- RIGL United States
- Employees
- CWBC N/A
- RIGL N/A
- Industry
- CWBC Major Banks
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- CWBC Finance
- RIGL Health Care
- Exchange
- CWBC Nasdaq
- RIGL Nasdaq
- Market Cap
- CWBC 345.4M
- RIGL 335.5M
- IPO Year
- CWBC 1996
- RIGL 2000
- Fundamental
- Price
- CWBC $20.72
- RIGL $18.98
- Analyst Decision
- CWBC Buy
- RIGL Buy
- Analyst Count
- CWBC 3
- RIGL 5
- Target Price
- CWBC $20.67
- RIGL $36.40
- AVG Volume (30 Days)
- CWBC 96.1K
- RIGL 212.0K
- Earning Date
- CWBC 07-22-2025
- RIGL 08-05-2025
- Dividend Yield
- CWBC 2.29%
- RIGL N/A
- EPS Growth
- CWBC N/A
- RIGL N/A
- EPS
- CWBC 0.65
- RIGL 2.08
- Revenue
- CWBC $120,399,000.00
- RIGL $203,077,000.00
- Revenue This Year
- CWBC $33.08
- RIGL $14.41
- Revenue Next Year
- CWBC $6.60
- RIGL $15.97
- P/E Ratio
- CWBC $31.84
- RIGL $9.06
- Revenue Growth
- CWBC 38.79
- RIGL 70.16
- 52 Week Low
- CWBC $15.57
- RIGL $8.61
- 52 Week High
- CWBC $22.89
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- CWBC 69.19
- RIGL 45.79
- Support Level
- CWBC $20.82
- RIGL $18.24
- Resistance Level
- CWBC $21.37
- RIGL $19.38
- Average True Range (ATR)
- CWBC 0.44
- RIGL 0.77
- MACD
- CWBC 0.12
- RIGL -0.04
- Stochastic Oscillator
- CWBC 80.06
- RIGL 43.64
About CWBC Community West Bancshares
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the Company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.